NICE guidelines on a digital therapeutic for insomnia

That this House welcomes new guidance MTG70 from the National Institute for Health and Care Excellence (NICE) on Sleepio, a digital therapeutic to treat insomnia and insomnia symptoms; understands that digital therapeutics are fully automated evidence-based treatments delivered in a digital format, designed to treat, manage, or prevent a medical condition; recognises this as a landmark moment for UK healthcare and innovation, with Sleepio the first-ever digital therapeutic to be evaluated by NICE; welcomes the rigour with which Sleepio was evaluated by NICE, with experts analysing Sleepio’s 12 Randomised Controlled Trials and its independent health economics evaluation to ensure it is safe, effective and cost-effective before recommending its use; celebrates Sleepio as an example of UK innovation, with Sleepio’s parent company Big Health founded by a Professor Colin Espie, a UK clinical psychologist and Professor of Sleep Medicine at University of Oxford, and Peter Hames, a former patient who experienced insomnia; recognises the role that innovation funding and support has played in generating evidence of Sleepio’s impact, with NICE evaluating data from a large-scale project funded by Innovate UK and rolled out with the Oxford Academic Health and Science Network and NHS practitioners in the Thames Valley; recognises the patient impact Sleepio could have for the nearly one in three adults who experience insomnia symptoms each week, if made available via the NHS; and the importance of good sleep for mental health and wellbeing; and recognises the resource and cost savings Sleepio could deliver for the health and care system.